Studies at a Glance
Severe Asthma | Lung Cancer Screening
Severe Asthma | Lung Cancer Screening
NOTE: Additional information on individual studies is forthcoming, pending IRB approval.
AIM4: Next Step (HUM00258497)
Regeneron | R668-AS-2373 | Lugogo
Asthma Uncontrolled with ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA In Comparison to ICS Dose Escalation to HIgh Dose ICS/LABA in Patients with Uncontrolled Asthma
Sanofi | DRI16762 | Lugogo
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to assess the efficacy, safety, and tolerability of subcutaneous SAR443765 in adult participants with moderate to severe asthma
AIRLYMPUS (HUM00262749)
Sanofi | ACT18301 | Lugogo
A randomized, Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to investigate the efficacy, safety, and tolerability of subcutaneous lunsekimig (SAR443765) in adult participants with high-risk asthma who are not currently eligible for biologic treatment
AstraZeneca | D8210C00003 | Lugogo
A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
Primary Endpoint: time to first composite endpoint for exacerbation (CompEx) event
Study assessing the long-term effect of Dupilumab (Dupixent) on prevention of lung function decline in patients with uncontrolled moderate to severe asthma.
Primary Endpoint: rate of change from Week 8 to Week 52 on post-BD FEV1 in ITT-FeNO population
Study designed to evaluate the effect of Benralizumab (Fasenra) on patients with uncontrolled severe, eosinophilic asthma despite a high dose ICS-based treatment regimen with an eosinophilic phenotype.
Primary Endpoint: percent change from baseline to EOT in eosinophil numbers in submucosa and in airway WA% as the overall median for airway generations 3 and 4 combined.
LEVANTE (HUM00259748)
AstraZeneca | D6830C00003 | Lugogo
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations
LIGHTHOUSE (HUM00234751)
Roche | GO44296 | Lugogo
Roche Lung Cancer Screening Collection Study with the purpose of developing a minimally invasive cancer detection method from a single blood draw.
REIMAGINE (HUM00248759)
GSK | 219871 | Mohan
A Prospective, Real-World, Interventional Study to Evaluate the Effect of Mepolizumab on Achieving Clinical Remission in Participants with Severe Asthma Primary Endpoint: number and proportion of participants adherent to NUCALA in the principal stratum who achieved clinical remission at 12 months.
Other Studies
Moderate Asthma | Future Participant Registry
Moderate Asthma | Future Participant Registry
AstraZeneca | D6930L00001 | Lugogo
This moderate asthma study is a prospective, multi-center, phase IV, interventional, open label, single-arm study to compare the rates of asthma exacerbation and healthcare resource use before and after switching the rescue therapy to AIRSUPRA.
Investigator Initiated | Lugogo
Primary Objective: to perform a screening visit to proactively evaluate potential subjects with asthma who have expressed interest in participating in clinical asthma research trials at Michigan Medicine.
● Eligible individuals have been diagnosed with asthma ≥12 months and are currently taking medication for asthma control.